B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools

Ioannis Parodis¹,²*, Mariele Gatto³ and Christopher Sjöwall⁴

¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ³Unit of Rheumatology, Department of Medicine, University of Padua, Padua, Italy, ⁴Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

B cell hyperactivity is a hallmark of the complex autoimmune disease systemic lupus erythematosus (SLE), which has justified drug development focusing on B cell altering agents during the last decades, as well as the off-label use of B cell targeting biologics. About a decade ago, the anti-B cell activating factor (BAFF) belimumab was the first biological agent to be licensed for the treatment of adult patients with active yet non-renal and non-neuropsychiatric SLE, to later be expanded to include treatment of pediatric SLE and, recently, lupus nephritis. B cell depletion is recommended as an off-label option in refractory cases, with the anti-CD20 rituximab having been the most used B cell depleting agent to date while agents with a slightly different binding specificity to CD20 such as obinutuzumab have also shown promise, forming a part of the current pipeline. In addition, terminally differentiated B cells have also been the targets of experimental therapies, with the proteasome inhibitor bortezomib being one example. Apart from being promising drug targets, B and plasma cells have also shown promise in the surveillance of patients with SLE, especially for monitoring B cell depleting or B cell altering therapies. Inadequate B cell depletion may signify poor expected clinical response to rituximab, for example, while prominent reductions in certain B cell subsets may signify a protection against flare development in patients treated with belimumab. Toward an era with a richer therapeutic armamentarium in SLE, including to a large extent B cell altering treatments, the challenge that emerges is to determine diagnostic means for evidence-based therapeutic decision-making, that uses clinical information, serological markers, and gene expression patterns to guide individualized precision strategies.

KEYWORDS
systemic lupus erythematosus, B cells, B lymphocyte, plasma cells, plasmablasts, therapy, biologics, lupus nephritis

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that is characterized by a multiple organ involvement and a prominent heterogeneity of clinical symptoms and disease severity (1). While the treatment of
SLE has been non-targeted for many years, mainly comprising antimalarial agents (2), glucocorticoids, and broad immunosuppressants that hamper inflammation in a non-specific manner (3), more selective therapeutic modalities have been used for SLE during the last decades (4), including B cell targeting therapies (5).

Belimumab, a monoclonal antibody that binds to the soluble form of the B cell activating factor belonging to the tumor necrosis family (BAFF; also known as B lymphocyte stimulator, BlyS), was approved for the treatment of SLE in 2011 after two successful phase III clinical trials (6, 7); it was the first in history biological agent to be approved for SLE (8), lending credence to the notion that B cells are central in the pathogenesis of SLE (9). Rituximab, an anti-CD20 B cell depleting monoclonal antibody has been used as an off-label therapeutic option since even earlier (10, 11), and is still used in difficult to treat or refractory cases despite serial failures of clinical trials to show added value on top of standard therapy (3). In this review, we summarize evidence for B cell and plasma cell targeting therapies in SLE, and advocate for the use of B cells as important tools not only as treatment targets, but also disease surveillance.

Loss of self-tolerance is a distinctive feature in SLE pathogenesis, leading up to immune responses toward endogenous nuclear and cytoplasmic components. Terminally differentiated antibody-secreting B cells i.e., plasmablast and long-lived plasma cell clones constitute the main producers of autoantibodies against such endogenous antigens, contributing to tissue injury and maintenance of the inflammatory milieu through immune complex formation and induction of type I interferon-mediated proinflammatory cytokine production. Autoantibodies such as anti-double stranded DNA (anti-dsDNA) and anti-Smith (Sm) antibodies are considered fairly specific for SLE and are associated with clinical disease features (12), while circulating anti-dsDNA levels oftentimes follow SLE disease activity (13, 14). Importantly, autoantibody production is not the only mechanism through which B cells contribute to SLE pathogenesis, as evidenced in murine lupus models where B cells that did not secrete autoantibodies still were important for disease progression (15); thus, the constantly hyperactive B cell lineages in SLE are also important for antigen presentation to T cells and cytokine secretion (16), or expression of toll-like receptors (TLRs) (17).

To characterize B cells, surface markers are used, such as CD19, CD20, and CD22, expressed at different stages of B cell maturation. B cell responses in SLE are currently hampered by two main means i.e., (i) BAFF inhibition through belimumab, and (ii) B cell depletion through anti-CD20 agents, such as rituximab, obinutuzumab, and ofatumumab. BAFF is a member of the tumor necrosis factor ligand superfamily and is mainly produced by myeloid and stromal cells (18). BAFF contributes to B cell survival, proliferation, and antibody production, through binding to three receptors expressed on the surface of B cells at different maturation stages i.e., the BAFF-Receptor (BAFF-R; also known as BlyS receptor 3, BR3), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and B cell maturation antigen (BCMA) (19). Notably, BAFF levels have been demonstrated to be elevated in patients with SLE compared with healthy controls and show correlates with disease activity (20–23). Apart from BAFF, B cell stimulation is also induced by cytokines such as type I interferons, interleukin (IL)-6, IL-21, as well as a proliferation-inducing ligand (APRIL), the latter mainly contributing to plasma cell survival (24, 25).

### Targeting B cells to treat SLE

Early uncontrolled studies of the chimeric anti-CD20 monoclonal antibody rituximab in SLE showed promise, but two phase III randomized controlled trials (RCTs), the EXPLORER trial in non-renal lupus (26) and the LUNAR trial in lupus nephritis (27), failed to meet their primary endpoints (28). This notwithstanding, rituximab has been used off-label for the treatment of cases of SLE and lupus nephritis that have not been responsive to standard therapy (3, 29, 30). While lupus nephritis, a potentially life-threatening condition (31), has been the most common SLE manifestation managed with rituximab in several centers, rituximab has also been used to treat severe polyarthritis, hematological SLE disease, especially severe haemolytic anemia or autoimmune thrombocytopenia, and neuropsychiatric SLE (32–37). However, it is worth noting that rituximab use has also raised concerns regarding adverse events, such as infusion-related reactions (38–40), late-onset neutropenia (41), and hypogammaglobulinaemia (42, 43).

In addition to rituximab, the humanized anti-CD20 monoclonal antibody ocrelizumab was evaluated in a phase III trial of severe lupus nephritis, which however was terminated due to serious infections (44); for this reason, ocrelizumab was not studied further in the context of SLE. The humanized anti-CD20 monoclonal antibody obinutuzumab has a different binding specificity to the CD20 molecule, resulting in superior cytotoxic effects for B cells over rituximab (45); obinutuzumab was studied in a phase II trial of lupus nephritis and showed ability to induce complete renal response (46). The prospect of obinutuzumab for the treatment of lupus nephritis is currently tested in a phase III clinical trial (NCT04221477). Ofatumumab is a fully human anti-CD20 monoclonal antibody that is approved for the treatment of chronic lymphocytic leukemia (47) and has shown promise in small studies of SLE, mainly used to treat lupus nephritis, immune-mediated thrombocytopenia, and autoimmune haemolytic anemia (48–51). Obinutuzumab and ofatumumab are considered viable options for patients in whom rituximab was effective but adverse events, namely infusion reactions, resulted in discontinuation (49), or for patients in whom rituximab did not induce complete B cell depletion (39).
Lastly, the humanized monoclonal antibody epratuzumab is directed against CD22, and while it showed promising results regarding both tolerability and efficacy in a phase Ib trial (52, 53), two subsequent phase III trials failed to prove efficacy (54).

**Targeting plasma cells**

While most B cell targeting drugs currently used in SLE mainly exert their effects on B cells of early maturation stages, plasmablasts, and short-lived plasma cells (55), proteasome inhibition affects long-lived plasma cells and has been used in severe therapy-resistant SLE cases (56–60). Proteasome inhibition results in accumulation of defective immunoglobulin chains, endoplasmic reticulum stress, misfolded proteins, and ultimately plasma cell apoptosis (61, 62). Being large-scale antibody producers, long-lived plasma cells are highly sensitive to proteasome inhibition (58). In addition, proteasome inhibitors also hamper the production of pro-inflammatory cytokines through regulation of NF-κB signaling (63).

Bortezomib, a dipeptide containing a boron atom that exerts its effects on plasma cells by binding with high affinity and specificity the catalytic site of the 26S proteasome, is approved for the treatment of mantle cell lymphoma and multiple myeloma (64). The prospect of bortezomib in SLE (65) gained promise after experiments in murine lupus, and reports of bortezomib use to treat allograft rejection after kidney transplantation (66, 67). In a recent nationwide study from Sweden, the current clinical experience based on 12 patients who received bortezomib for refractory SLE was reported (68). The therapeutic effects of bortezomib combined with glucocorticoids were beneficial in a majority of the patients with severe and life-threatening SLE manifestations that had been irreversible to conventional immunosuppressive agents; these effects included alleviation of proteinuria levels and complement consumption, as well as seroconversion from positive to negative anti-dsDNA antibody status (68). Safety signals that emerged in this study mainly comprised the potential risk for infections and hypogammaglobulinemia (68).

On the other hand, concerns may argue that sole bortezomib treatment might not be as sufficient in autoimmune conditions as in non-autoimmune hematological diseases, due to a rapid bone marrow repopulation with short-lived plasma cells and subsequent rise in autoantibody levels that occur upon bortezomib withdrawal, which is likely attributable to the limited effects of bortezomib on bone marrow B and T cell precursors (62). Additionally, the only randomized trial that employed bortezomib in SLE did not demonstrate superiority of bortezomib over placebo in clinical or serological efficacy (69). Nevertheless, careful interpretation of these results should be entailed due to the limited number of patients enrolled and the choice of endpoints. In fact, proteasome inhibition in SLE might be an option in severe, refractory cases (68), and might require additional subsequent B cell depleting modalities to ensure long-term efficacy. In this regard, plasma cells may also be targeted through blockade of CD38. Daratumumab is a monoclonal antibody against CD38 approved for multiple myeloma, which has been successfully used in patients with refractory SLE who previously had received bortezomib (70), lending merit for targeting terminally differentiated B cells in recalcitrant forms of SLE using one or multiple agents.

**Targeting B cell-related cytokines**

BAFF has been a central target molecule in drug development for SLE, due to its key roles in B cell homeostasis. Targeting BAFF has been proven a successful therapeutic strategy with the approval of the anti-BAFF monoclonal antibody belimumab, formerly also known as Lympho-Stat B, after two successful phase III RCTs (6, 7). In different studies, patients with low B cell counts, high BAFF levels, serologically active disease, limited or no established organ damage, and no exposure to cigarette smoking have been shown to be more benefited from belimumab therapy (71–80). Safety signals reported during belimumab therapy mostly concern infusion reactions and mild infectious events (6, 7, 72, 81), and some caution was raised during the early post-market phase about the risk of psychiatric disorders (82), but the drug has shown an excellent overall safety profile, also over a longer term (83).

Another BAFF-inhibiting agent is atacicept, a receptor construct that combines TACI with the Fc fragment of human IgG, thus inhibiting both BAFF and APRIL (84). Atacicept was evaluated in a clinical trial of lupus nephritis, which was terminated prematurely due to adverse events such as hypogammaglobulinemia and infections (85); however, the development of atacicept for the treatment of SLE has not been fully abandoned.

The fusion protein blisibimod consists of four high-affinity BAFF-binding domains and the Fc domain of human IgG1; in contrast to belimumab that only binds to the soluble counterpart of BAFF, blisibimod targets both soluble and membrane-bound BAFF. Following a promising dose-ranging phase Ib clinical trial of SLE that determined a safe and effective dose (86), a subsequent phase III clinical trial failed unfortunately to prove efficacy (87).

Tabalumab is a fully human monoclonal antibody that also targets both soluble and membrane-bound BAFF. Two phase III clinical trials of tabalumab in SLE have been completed, of which only one met its primary endpoint (88, 89), being the reason why its development for SLE was stopped. However, it is worth noting that key secondary endpoints were met in both trials, justifying the rationale of targeting both the cleaved and membrane-bound BAFF molecule (90, 91).

Anifrolumab is a recently developed monoclonal antibody against the type I interferon (IFN) receptor (IFNAR), hence
with inhibitory capability on the type I IFN pathway. While type I IFNs are mainly produced by plasmacytoid dendritic cells (pDCs) and resident cells in target tissues (92), B cells are highly sensitive to the IFN pleiotropic action and are prompted to differentiation and activation upon IFN-mediated signaling (24). The successful phase Iib trial of anifrolumab in patients with moderate or severe SLE (93) put the grounds for the conception of patient stratification based on endotypic features, e.g., the magnitude of the IFN signature, and in contrast to the failure of the first phase III trial of anifrolumab in SLE (TULIP1) (94), the drug was successful in the subsequent phase III trial TULIP2 (95). Based on an overall evaluation of the primary and key secondary endpoints of the TULIP trials, anifrolumab received approval by regulatory authorities for use in SLE. Additionally, a phase II trial of anifrolumab in active lupus nephritis showed initial promise (96) and prompted an ongoing phase III trial. Safety signals reported for anifrolumab therapy mostly concern reactivation of opportunistic infections, particularly by varicella zoster virus (VZV), due to the IFN blockade, especially in patients with kidney involvement (97).

While the therapeutic armamentarium for SLE has been enriched with new therapeutic modalities that directly or indirectly target B cells of diverse maturation stages, the identification of the best patient candidates for the different treatments remains lacunose. Clinical features and traditional serological markers (71–80), as well as particular immunological signatures (94, 95), have been introduced as potential predictors of therapeutic responses, representing important steps toward more informed decision-making processes, yet optimisation is still limited by major knowledge gaps regarding in-depth characterization of underlying mechanisms, and the impact those mechanisms have on the individual patient.

### Combination therapies to target B cells

The observed rise in BAFF levels upon treatment with rituximab (98) has been speculated to be one of the reasons why clinical trials of rituximab in SLE have failed, providing grounds to the rationale for combining rituximab with belimumab to achieve better B cell responses (23, 98–100). This approach has recently been evaluated in patients with SLE within the frame of e.g., the BEAT Lupus (101, 102) and BLISS-BELIEVE (103) trials. The latter, however, failed to show superior disease control with the addition of a single cycle of rituximab on top of belimumab treatment over that achieved by belimumab treatment alone, while more serious infections were seen in the combination group (104). Furthermore, the concept of combining B cell therapies has also been studied in the context of lupus nephritis, e.g., in the Rituximab and Belimumab for Lupus Nephritis (CALIBRATE; NCT02260934) (105) and Synergetic B cell Immunomodulation in SLE (SynBioSe) trials (SynBioSe 1: NCT02284984 (106); SynBioSe 2: NCT03747159). While the CALIBRATE study failed to reach its primary endpoint i.e., achievement of renal response at week 48, biological effects in the form of decreased anti-dsDNA antibody levels and modification of the B cell pool composition favored the addition of belimumab to a therapeutic regimen comprising rituximab and cyclophosphamide. Importantly, no safety signals emerged for this combination.

A summary of recent or ongoing trials of agents that directly or indirectly alter the B cell constitution in patients with SLE and lupus nephritis is presented in Table 1. Figure 1 illustrates the main mode of action of compounds discussed in the present review.

### The prospect of B cells as surveillance tools

Changes in the circulating B cell pool are expected upon B cell targeting therapies and have been described in response to anti-CD20 (22, 39, 111) and anti-BAFF (74, 112, 113) therapies. On the other hand, little data has piled up so far concerning the potential role of B cell changes as measurable biomarkers of response to therapy or as heralds of disease flares.

Recently, we analyzed data from three phase III RCTs of belimumab i.e., BLISS-76 (NCT00410384) (7), BLISS-SC (NCT01484496) (114), and BLISS Northeast Asia (NEA; NCT01345253) (115) and pinpointed specific relative to baseline percentage changes across different circulating CD19+ B cell and plasma cell subsets occurring in SLE patients after treatment commencement for active disease with standard therapy with or without add-on belimumab to be associated with treatment response (116) or disease flares (117). Within a pooled cohort of 1712 patients with SLE, treatment responders showed more prominent decreases from baseline through week 52 in CD19+CD20+CD27− naïve B cells, CD19+CD20−CD27bright plasmablasts, and CD19+CD20−CD138+ long-lived plasma cells, and a more prominent rapid (through week 8) and early (through week 24) expansion of CD19+CD20−CD27bright memory B cells compared with non-responders (116). Conversely, patients who developed severe flares showed less prominent early decreases in CD19+CD20−CD138+ long-lived plasma cells and CD19+CD27brightCD38bright SLE-associated plasma cells (117).

In an analysis of B cell changes in relation to renal flare development within the same SLE population from trials of belimumab (unpublished data), patients who developed renal flares showed a more prominent rapid decrease in CD19+CD20+CD138− short-lived plasma cells and CD19+CD20−CD27bright plasmablasts compared with patients who did not flare, followed by a subsequent return. Remarkably, more prominent rapid reductions in CD19+CD27−CD24brightCD38bright transitional B cells...
| Drug name | Mechanism | Phase | Endpoint | Results | References |
|-----------|-----------|-------|----------|---------|------------|
| **Adaptive immunity** | | | | | |
| BIIB059 | anti-BDCA2 | II SLE/CLE | DAS28 w24 CLASI w16 | Successful | NCT02847598 |
| | | | SRI-4 w52 | Ongoing | NCT04895241, NCT04961567 |
| Obinutuzumab | anti-CD20 | II LN | CRR w52 | Successful | Furie et al. (46) |
| | | | CRR w76 | Ongoing | NCT04221477 |
| Belimumab | anti-BAFF | III LN | PRR w104 | Successful | Furie et al. (107) |
| Rituximab-belimumab | Sequential CD20-BAFF inhibition | II SLE | IgG anti-dsDNA w52 | Successful | Shipa et al. (102) |
| Rituximab-belimumab (CALIBRATE) | Sequential CD20-BAFF inhibition | II LN | Safety (met), Secondary: CR or PR w48 (not met) | Failed | Atisha-Fregoso et al. (105) |
| Belimumab-rituximab (BLISS-BELIEVE) | Sequential BAFF-CD20 inhibition | III SLE | Remission w52 | Failed | Aranow et al. (104) |
| Dapirolizumab | anti-CD40L | II SLE | BICLA w24 | Successful | NCT02804763 |
| | | | BICLA w48 | Ongoing | NCT04294667 |
| **Small molecules** | | | | | |
| Baricitinib | anti-JAK1 | II SLE | Resolution of arthritis or rash w24 | Successful | Wallace et al. (108) |
| Baricitinib | anti-JAK1 | III SLE | SRI-4 w52 | Terminated | NCT03616912 |
| BRAVE I, II | | | | | NCT03616964 |
| Tofacitinib | anti-JAK1/3 | I SLE | Safety | Drug stopped | Hasni et al. (109) |
| BMS-986165 | anti-TYK2 | II LN | Safety, Secondary: CRR or PRR w24 | Terminated | NCT03943147 |
| Deucravacitinib | anti-TYK2 | II DLE, SCLE | Change in CLASI-A w16 | Ongoing | NCT04857034 |
| Upadacitinib | anti-JAK1 | II SLE | SRI-4 w24 | Ongoing | NCT03978520 |
| **Indirect impact on B cells** | | | | | |
| Anifrolumab | anti-IFNAR | III SLE | SRI-4 w52 | Failed | Furie et al. (94) |
| | | | BICLA w52 | Successful | Morand et al. (95) |
| | | | CRR w52 | Ongoing | NCT05138133 |
| Secukinumab | anti-IL17A | II LN | CRR w52 | Ongoing | NCT04181762 |
| Ustekinumab | anti-IL12/23 | II SLE | SRI-4 w24 | Successful | van Vollenhoven et al. (110) |

BAFF, B cell activating factor belonging to the tumor necrosis factor family; BDCA2, blood dendritic cell antigen 2; BICLA, BILAG 2004-Based Composite Lupus Assessment; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; CLE, cutaneous lupus erythematosus; CR, complete response; CRR, complete renal response; DLE, discoid lupus erythematosus; IFNAR, interferon-α/β receptor; JAK, Janus kinase; LN, lupus nephritis; PERR, Primary efficacy renal response; PR, partial response; PRR, partial renal response; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic lupus erythematosus; SRI, SLE Responder Index; TYK, tyrosine kinase; w, week.

and CD19+CD20−CD138+ peripheral long-lived plasma cells were associated with a protection against renal flares in belimumab-treated patients.

It is worth noting that B cell changes in these analyses were mainly related to treatment effectiveness rather than the mechanism of the drug employed. However, considering its mode of action, belimumab is expected to impact on B cells of early maturation stages, as shown previously (74, 112, 113, 118), and decreasing B cell counts may be expected to predict favorable responses to belimumab, as previously demonstrated for rituximab in patients achieving adequate B cell depletion (22, 39). Moreover, in a real-life observational study, immunological responses to belimumab preceded overt clinical improvements (74). Thus, since changes in circulating B cell subsets may be expected to occur shortly upon therapy commencement, such changes could prove a useful tool in the treatment and disease monitoring in patients with SLE, complementary to traditional serological biomarkers such as anti-dsDNA and complement levels, which may be less sensitive to change. Lastly, the use of relevant molecules in the prediction of response to therapies is expected to advance treatment selection and monitoring in the future. High
BAFF levels, for instance, have been associated with favorable clinical response to treatment with belimumab (72), but also imminent flare in patients with SLE on non-biological standard therapy (119).

Concluding remarks

SLE is characterized by breach of self-tolerance and constant B cell hyperactivity. While the contribution of B cells to disease initiation is unclear, they have key roles in the pathogenesis of established SLE and the maintenance of the chronic inflammatory milieu. Several B cell targeting therapeutic modalities have an established role in the SLE treatment armamentarium, while other are in the pipeline. Optimized use of B cell altering therapeutic approaches would require effective identification of patients who would be more likely to benefit from B cell therapies based on their clinical and immunological phenotypes. In this regard, the usefulness of B cell and plasma cell levels and alterations as markers of treatment response or flare development has not been thoroughly explored, but recent data show merit and ratify further survey.

Author contributions

All authors contributed to the manuscript draft, critically reviewed all parts of the manuscript, accepted its final version prior to submission, and account for its content.

Funding

IP was funded by grants from the Swedish Rheumatism Association (R-941095), King Gustaf V’s 80-year Foundation (FAI-2020-0741), Professor Nanna Swartz Foundation (2020-00368), Ulla and Roland Gustafsson Foundation (2021-26), Region Stockholm (FoUI-955483) and Karolinska Institutet. CS was funded by the Swedish Rheumatism Association (R-939149), Region Östergötland (ALF grants; RO-960604), King Gustaf V’s 80-year Anniversary foundation (FAI-2020-0663), and King Gustaf V and Queen Victoria’s Freemasons foundation.
The funders had no role in the design of the study, the analyses or interpretation of data, or the writing of the manuscript.

Acknowledgments

The authors would like to thank GlaxoSmithKline for providing data from the BLISS-76 (NCT00410384), BLISS-SC (NCT01484496), and BLISS-NEA (NCT01345253) trials through the CSDR consortium.

Conflict of interest

Author IP has received research funding and/or honoraria from Agen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis, and F. Hoffmann-La Roche AG.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Kaal A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. *Nat Rev Dis Primers.* (2016) 2:16039. doi: 10.1038/nrdp.2016.39
2. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis.* (2010) 69:20–8. doi: 10.1136/ard.2008.101766
3. Faznourikas A, Kostopoulou M, Alunno A, Artinger M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis.* (2019) 78:736–45. doi: 10.1136/annrheumdis-2019-215089
4. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. *Nat Rev Rheumatol.* (2015) 15:30–48. doi: 10.1038/nrrheum.2014.18-0133-2
5. Parodis I, Stockfelt M, Sjovall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. *Front Med (Lausanne).* (2020) 7:316. doi: 10.3389/fmed.2020.00316
6. Navarra SV, Guzman RM, Gallagher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet.* (2011) 377:721–31. doi: 10.1016/S0140-6736(10)61354-2
7. Furse R, Petroi M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum.* (2011) 63:3918–30. doi: 10.1002/art.30613
8. Parodis I, Axelsson M, Gunnarsson I. Belimumab in systemic lupus erythematosus: a practice-based view. *Lupus.* (2013) 22:572–80. doi: 10.1177/0961203313476154
9. Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. *BioDrugs.* (2013) 27:85–95. doi: 10.1007/s40259-013-0015-8
10. Leandro MJ, Edwards JC, Cambridge EH, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. *Arthritis Rheum.* (2002) 46:2673–7. doi: 10.1002/art.10541
11. Gunnarsson I, Sundelin B, Jonndottir T, Jacobsson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. *Arthritis Rheum.* (2007) 56:1263–72. doi: 10.1002/art.22505
12. Swaak AJ, Huyzen V, Nosent JC, Smeenk RJ. Antinuclear antibody profile in relation to specific disease manifestations of systemic lupus erythematosus. *Clin Rheumatol.* (1990) 9:82–94. doi: 10.1007/BF02205555
13. Encosson H, Sjovall C, Wirenstrom L, Dahlke C, Kastborn A, Ronnellid J, et al. Four anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity. *J Rheumatol.* (2015) 42:817–25. doi: 10.3899/jrheum.140677
14. Fredlund M, Wetterer J, Dahlke C, Dahlström O, Skogh T, Ronnellid J, et al. Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease. *Clin Exp Immunol.* (2020) 199:245–54. doi: 10.1111/cei.13402
15. Chan OT, Hanzum LG, Haberman AM, Madaï MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. *J Exp Med.* (1999) 189:1639–48. doi: 10.1084/jem.189.10.1639
16. Suzuki N, Sakane T. Induction of excessive B cell proliferation and differentiation by an in vitro stimulus in culture in human systemic lupus erythematosus. *J Clin Invest.* (1989) 83:937–44. doi: 10.1172/JCI113979
17. Klonowska-Szymczyk A, Wolska A, Robak T, Cebula-Obrzut B, Smolewska P, Robak E. Expression of toll-like receptors 3, 7, and 9 in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. *Mediators Inflamm.* (2014) 2014:814188. doi: 10.1155/2014/814188
18. Mackay F, Schneider P. Cracking the BAF code. *Nat Rev Immunol.* (2009) 9:491–502. doi: 10.1038/nri2572
19. Vincent FB, Morand EF, Schneider P, Mackay F. The BAF/APRIL system in SLE pathogenesis. *Nat Rev Rheumatol.* (2014) 10:365–73. doi: 10.1038/rrheum.2014.33
20. Petri M, Stohl W, Chatham W, McCune WL, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. *Arthritis Rheum.* (2008) 58:2453–61. doi: 10.1002/art.23678
21. Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Munoz-Valle JF, et al. Association of BAFF, APRIL serum levels, and disease activity in systemic lupus erythematosus. *Arthritis Rheum.* (2016) 73:401–11. doi: 10.1002/art.39524
22. Vital EM, Dass S, Buch MH, Henshaw K, Pease CT, Martin MF, et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. *Arthritis Rheum.* (2011) 63:3038–47. doi: 10.1002/art.30466
23. Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, et al. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. *Lupus Sci Med.* (2015) 2:e00061. doi: 10.1136/lupus-2014-00061
24. Ritenblom I, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. *Lupus Sci Med.* (2019) 6:e000270. doi: 10.1136/lupus-2018-000270
Analysis of rituximab infusion reactions to rituximab in systemic lupus erythematosus: a retrospective evaluation of rituximab trial. *Arthritis Rheum.* (2010) 62:221–33. doi: 10.1002/art.27233

Rovin BH, Furie R, Latini K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum.* (2012) 64:1215–26. doi: 10.1002/art.33439

Tsouma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. *Expert Opin Biol Ther.* (2013) 13:723–37. doi: 10.1517/14712598.2013.764411

Eko SL, van Vollenhoven RF. Rituximab and lupus—a promising pair? *Curr Rheumatol Rep.* (2014) 16:444. doi: 10.1007/s11934-014-0444-5

Fonouniakias A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Rajema J, et al. 2016. *Ann Rheum Dis.* 2016. 00016336 Ann Rheum Dis. European Reference Network for Rheumatology and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. *Ann Rheum Dis.* (2020) 79:713–23. doi: 10.1136/annrheumdis-2020-216924

Anders HJ, Saxena R, Zhao MH, Parodis I, salmon JE, Mohan C. Lupus nephritis. *Nat Rev Dis Primers.* (2020) 6:07. doi: 10.1038/s41571-019-0141-9

Jonsdottir T, Gunnarsdottir I, Risselada A, Henriksson EW, Klareos L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. *Ann Rheum Dis.* (2008) 67:330–4. doi: 10.1136/ard.2007.079985

Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity and Rituximab registry. *Arthritis Rheum.* (2010) 62:2458–66. doi: 10.1002/art.27541

Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, Callejas JL, Martinez-Berriotxoa A, Pallares L, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. *Clin Exp Rheumatol.* (2010) 28:468–76.

Witt M, Grunke M, Proft F, Baeuerle M, Aringer M, Burmester G, et al. German Registry of Autoimmune Diseases. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID). *Lupus.* (2013) 22:1142–9. doi: 10.1177/0961203313503912

Ryden-Aulin M, Boumpas D, Bulbik I, Callejas Rubio JL, Camin-Salas-Montero L, et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. *Lupus Sci Med.* (2016) 3:e000163. doi: 10.1093/lupus/e6v013

Alshaiki F, Obaid E, Almuallim A, Taha R, Al-Haddad H, Almoallim H. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. *Eur J Rheumatol.* (2018) 5:118–26. doi: 10.14712/eurjrheum.2018.17096

Hennessey A, Lukawska J, Cambridge G, Isenberg D, Leandro M. Adverse effects of rituximab in refractory lupus: a meta-analysis. *Semin Arthritis Rheum.* (2015) 45:353–44. doi: 10.1016/j.semarthrit.2015.06.014

Md Yusof MY, Shaw D, El-Sherbini YM, Dunn E, Rawston AC, Emery P, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. *Ann Rheum Dis.* (2017) 76:1829–36. doi: 10.1136/annrheumdis-2017-211191

Hennessy A, Lukawska J, Cambrige G, Ivensberg D, Leandro M. Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. *BMC Rheumatol.* (2019) 3:32. doi: 10.1186/s42412-019-0082-7

Parodis I, Soder E, Faustin F, Kasza Z, Samuelsson I, Zackert A, et al. Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. *Lupus.* (2018) 27:1470–8. doi: 10.1177/0961203318777116

Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, et al. Rituximab-associated hypoagammaglobulinemia in autoimmune disease. *Front Immunol.* (2021) 12:671503. doi: 10.3389/fimmu.2021.671503

Padovan R, Fulceri M, Gatto M, Polito P, Doria A, Schiavon F. Rituximab-associated hypoagammaglobulinemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. *Clin Exp Rheumatol Med Suppl.* (2020) 24:128–88.

Myler J, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from two phase III randomized, double-blind, placebo-controlled trials. *Arthritis Rheum.* (2012) 64:1215–26. doi: 10.1002/art.34359

Parodis et al. /one.tnum/zero.tnum/three.tnum/three.tnum/eight.tnum/nine.tnum/fmed./two.tnum/zero.tnum/two.tnum/two.tnum/five.tnum/two.tnum/three.tnum/zero.tnum/four.tnum
Bortezomib provides effective therapy for antibody- and cell-mediated acute kidney injury based therapy for antibody-mediated rejection.

Targeting CD38 with daratumumab in refractory systemic lupus erythematosus.

B cell alterations during BAFF inhibition with belimumab in SLE.

High disease activity predictors of response.

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response.

An antibody- and cell-depletion effect of rituximab in patients with systemic lupus erythematosus and rheumatoid arthritis.

JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.

Interferon blockade in lupus: effects on antiviral immunity.

Early disease and low baseline levels as predictors of response to belimumab in patients with systemic lupus erythematosus in a real-life setting.

Results from a large, multicentric, nationwide study.

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus.

Efficacy and safety of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus.

Patients with systemic lupus erythematosus on rituximab: factors associated with sustained B cell depletion.

Durable renal response and safety with add-on belimumab in patients with lupus nephritis: results of a prematurely terminated trial.

Safety and failure of biological treatment in systemic lupus erythematosus: a critical analysis.

The half-life of leflunomide.

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.

EBioMedicine.
randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. (2019) 9:e025669. doi: 10.1136/bmjopen-2019-025669

102. Shima M, Embleton-Thirsk A, Parvaz M, Santos LR, Muller P, Chowdhury K, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus: a randomized controlled trial. Ann Intern Med. (2021) 174:1647–57. doi: 10.7326/M21-2078

103. Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RE, Gordon D, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE). BLISS-BELIEVE study protocol. BMJ Open. (2019) 9:e025687. doi: 10.1136/bmjopen-2018-025687

104. Aranow C, Allarct G, Amoura Z, Bruce I, Cagnoli P, Furie R, et al. Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX). Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study [abstract]. Arthritis Rheumatol. (2021) 73 (suppl 10).

105. Attila-Carrer S, Harris KM, Byron M, Ding L, Kanaparthi AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. (2021) 73:121–31. doi: 10.1002/art.41466

106. Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. (2018) 91:45–54. doi: 10.1016/j.jaut.2018.03.003

107. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. (2020) 383:1117–28. doi: 10.1056/NEJMoa2001180

108. Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. (2018) 392:222–31. doi: 10.1016/S0140-6736(18)31363-1

109. Hanai SA, Gupta S, Davis M, Poncio E, Temezgen-Oyedakin Y, Carlucci PM, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. (2021) 12:3391. doi: 10.1038/s41467-021-23361-z

110. van Vollenhoven RE, Hahn BH, Tsokos GC, Lipsky P, Gordon RM, Fei K, et al. Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study. J Rheumatol. (2022) 49:380–7. doi: 10.3899/jrheum.210805

111. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. (2021) 20:179–99. doi: 10.1038/s41573-020-00092-2

112. Jacoby AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. (2018) 62:201–10. doi: 10.1002/art.27189

113. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. (2012) 64:2328–37. doi: 10.1002/art.34400

114. Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week, randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. (2017) 69:1016–27. doi: 10.1002/art.40049

115. Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. (2018) 77:355–63. doi: 10.1136/annrheumdis-2017-211631

116. Parodis I, Gomez A, Lindblom J, Chow JW, Doria A, Gatto M. Early Changes in B and plasma cell subsets and traditional serological markers as predictors of SRI-4 response to therapy in systemic lupus erythematosus. Front Med (Lausanne). (2022) 9:852162. doi: 10.3389/fmed.2022.852162

117. Parodis I, Gomez A, Chow JW, Borg A, Lindblom J, Gatto M. Early B cell and plasma cell kinetics upon treatment initiation portend flares in systemic lupus erythematosus: a post-hoc analysis of three phase III clinical trials of belimumab. Front Immunol. (2022) 13:796508. doi: 10.3389/fimmu.2022.796508

118. Regola F, Piantoni S, Lowin T, Archetti S, Reggia R, Kumar R, et al. Association between changes in BlyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab. Front Pharmacol. (2019) 10:433. doi: 10.3389/fphar.2019.00433

119. Petri MA, van Vollenhoven RE, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. (2013) 65:2143–53. doi: 10.1002/art.37995